{"schema_version":"1.0","canonical_url":"https://patentable.app/patents/US-11279970","patent":{"patent_number":"US-11279970","title":"Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor","assignee":null,"inventors":[],"filing_date":"2018-02-26T00:00:00.000Z","publication_date":"2022-03-22T00:00:00.000Z","cpc_codes":["C12Q","C12Q","C12Q","G01N","G16H","C12Q","C12Q","C12Q","G01N"],"num_claims":8,"abstract":"The present disclosure describes methods of identifying a patient that is likely to be responsive to treatment with a protein arginine N-methyltransferase 5 (PRMT5) inhibitor. The methods include evaluating a biological sample from the patient for the presence of a spliceosome mutation or alteration, wherein the presence of the alteration indicates a higher likelihood for the patient to be responsive to treatment with the PRMT5 inhibitor than in the absence of the mutation or alteration."},"analysis":{"summary":null,"layman_explanation":null,"technical_analysis":null,"business_analysis":null,"faqs":null,"topics":[],"tech_cluster":null},"seo":{"title":"Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor","description":"The present disclosure describes methods of identifying a patient that is likely to be responsive to treatment with a protein arginine N-methyltransferase 5 (PRMT5) inhibitor. The methods include eval","keywords":[]},"attribution":{"source":"Patentable","source_url":"https://patentable.app","canonical_url":"https://patentable.app/patents/US-11279970","license":"CC-BY-4.0-like","license_terms":"AI-generated analysis on this page (summary, layman_explanation, technical_analysis, business_analysis, faqs) may be reused with attribution and a visible link back to the canonical URL above. Patent abstracts, claims, and bibliographic data are USPTO public domain.","required_link":"https://patentable.app/patents/US-11279970","citation_suggestion":"Patentable. \"Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor\" (US-11279970). https://patentable.app/patents/US-11279970","copyright_holder":"Nomic Interactive Technology LLC"},"links":{"html":"https://patentable.app/patents/US-11279970","json":"https://patentable.app/api/llm-context/US-11279970","site":"https://patentable.app","llms_txt":"https://patentable.app/llms.txt"},"generated_at":"2026-05-30T14:59:52.684Z"}